Other Clinical Trial - Study of Tazemetostat in Participants With Relapsed

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03664635` - MB-CART20.1 Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05370430` - BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL	Phase 1
Completed	`NCT03009344` - A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT03664635 - MB-CART20.1 Lymphoma

Phase 1/Phase 2

Recruiting

NCT05370430 - BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Phase 1

Completed

NCT03009344 - A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03456726
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	April 9, 2018
Completion date	December 17, 2021

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms